Нейротрофический фактор мозга (BDNF) и его диагностическая значимость при измерении в крови: аналитический обзор
https://doi.org/10.25789/YMJ.2020.71.27
Аннотация
В обзоре приведены основные сведения о биологической роли, содержании и регуляции нейротрофического фактора мозга (BDNF) в организме (раздел I), о концентрации BDNF в крови при нейропсихических заболеваниях (раздел II) и выполнен анализ сопряженности содержания BDNF в головном мозге и периферической крови (раздел III, основной).
Ключевые слова
человек,
нейротрофический фактор мозга (BDNF),
нейропсихические заболевания,
головной мозг,
кровь,
корреляция между мозгом и кровью
При поддержке: Бюджетное финансирование НИИФФМ на проведение поискового научного исследования 2016 года (результаты, относящиеся к рис. 1) и фундаментальных научных исследований (тема АААА-А16-116021010228-0).
Об авторах
А. А. Швайковская
Институт медицины и психологии В. Зельмана Новосибирского ГУ
Россия
Россия
Швайковская Анна Андреевна – студент
С. Я. Жанаева
НИИ физиологии и фундаментальной медицины
Россия
Россия
Жанаева Светлана Яковлевна – к.б.н.
А. В. Евсюкова
Институт медицины и психологии В. Зельмана Новосибирского ГУ
Россия
Россия
Евсюкова Александра Владиславовна – студент
М. А. Тихонова
НИИ физиологии и фундаментальной медицины
Россия
Россия
Тихонова Мария Александровна – д.б.н., зав. лаб.
К. В. Даниленко
НИИ физиологии и фундаментальной медицины
Россия
Россия
Даниленко Константин Васильевич – д.м.н., зам. директора по науч. и лечебной работе
Л. И. Афтанас
НИИ физиологии и фундаментальной медицины
Россия
Россия
Афтанас Любомир Иванович – д.м.н., проф., акад. РАН, директор института
Список литературы
1. Левчук Л. А. Роль BDNF в патогенезе неврологических и психиатрических расстройств/ Л. А. Левчук //Современные проблемы науки и образования. – 2018. – №. 6. – С. 58.
2. Склероз гиппокампа: патогенез, клиника, диагностика, лечение/ Д.Н. Копачев [и др.] // Вопросы нейрохирургии» имени НН Бурденко. – 2016. – Т. 80, №. 4. – С. 109-116.
3. A 6-day combined wake and light therapy trial for unipolar depression / K. V. Danilenko, M. Y. Lebedinskaia, E. V. Gadetskaia [et al.] // Journal of affective disorders. – 2019. – V. 259. – P. 355-361.
4. A method for reproducible measurements of serum BDNF: comparison of the performance of six commercial assays / A. Polacchini, G. Metelli, R. Francavilla [et al.] // Scientific reports. – 2015. – V. 5. – P. 17989.
5. A study of brain and serum brain-derived neurotrophic factor protein in Wistar and Wistar-Kyoto rat strains after electroconvulsive stimulus / C. Kyeremanteng, J. James, J. Mackay [et al.] // Pharmacopsychiatry. – 2012. – V. 45. – № 06. – P. 244-249.
6. Acute low-dose ketamine produces a rapid and robust increase in plasma BDNF without altering brain BDNF concentrations / M. Le Nedelec, P. Glue, H. Winter [et al.] // Drug delivery and translational research. – 2018. – V. 8. – № 3. – P. 780-786.
7. Altered expression of BDNF, BDNF pro-peptide and their precursor proBDNF in brain and liver tissues from psychiatric disorders: rethinking the brain–liver axis / B. Yang, Q. Ren, J.C. Zhang [et al.] //Translational psychiatry. – 2017. – V. 7. – № 5. – P. e1128-e1128.
8. Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) patients are characterized by increased BDNF serum levels / F. Angelucci, G. Spalletta, F. di Iulio [et al.] //Current Alzheimer Research. – 2010. – V. 7. – № 1. – P. 15-20.
9. Barde Y. A., Edgar D., Thoenen H. Purification of a new neurotrophic factor from mammalian brain //The EMBO journal. – 1982. – V. 1. – № 5. – P. 549-553.
10. BDNF and epilepsy: too much of a good thing? / D. K. Binder, S. D. Croll, C.M. Gall [et al.] // Trends in neurosciences. – 2001. – V. 24. – № 1. – P. 47-53.
11. BDNF concentrations are decreased in serum and parietal cortex in immunotoxin 192 IgGSaporin rat model of cholinergic degeneration / F. Angelucci, F. Gelfo, P. De Bartolo [et al.] // Neurochemistry international. – 2011. – V. 59. – № 1. – P. 1-4.
12. BDNF promoter I methylation correlates between post-mortem human peripheral and brain tissues / L. Stenz, S. Zewdie, T. Laforge-Escarra [et al.] // Neuroscience research. – 2015. – V. 91. – P. 1-7.
13. BDNF serum levels with respect to multidimensional assessment in amyotrophic lateral sclerosis / L. Tremolizzo, A. Pellegrini, E. Conti [et al.] //Neurodegenerative Diseases. – 2016. – V. 16. – № 3-4. – P. 192-198.
14. BDNF: a key factor with multipotent impact on brain signaling and synaptic plasticity / P. Kowiański, G. Lietzau, E. Czuba [et al] //Cellular and molecular neurobiology. – 2018. – V. 38. – №. 3. – P. 579-593.
15. BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases / B. Lu, G. Nagappan, X. Guan [et al.] // Nature Reviews Neuroscience. – 2013. – V. 14. – № 6. – P. 401-416.
16. Benarroch E. E. Brain-derived neurotrophic factor Regulation, effects, and potential clinical relevance // Neurology. – 2015. – P. 10.1212/WNL.0000000000001507.
17. Blood BDNF concentrations reflect brain-tissue BDNF levels across species / A. B. Klein, R. Williamson, M. A. Santini [et al.] // International Journal of Neuropsychopharmacology. – 2011. – V. 14. – № 3. – P. 347-353.
18. Brain-derived neurotrophic factor and antidepressive effect of electroconvulsive therapy: systematic review and meta-analyses of the preclinical and clinical literature / M. Polyakova, M. L. Schroeter, B. M. Elzinga [et al.] // PLoS one. – 2015. – V. 10. – № 11.
19. Brain-derived neurotrophic factor in adjuvant-induced arthritis in rats. Relationship with inflammation and endothelial dysfunction / M. Pedard, C. Demougeot, C. Prati [et al.] //Progress in Neuro-Psychopharmacology and Biological Psychiatry. – 2018. – V. 82. – P. 249-254.
20. Brain-derived neurotrophic factor in brain disorders: focus on neuroinflammation / B. L. Giacobbo, J. Doorduin, H. C. Klein [et al.] // Molecular neurobiology. – 2019. – V. 56. – № 5. – P. 3295-3312.
21. Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation / H. Fujimura, C. A. Altar, R. Chen [et al.] // Thrombosis and haemostasis. – 2002. – V. 87. – № 04. – P. 728-734.
22. Brunoni A. R., Lopes M., Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression // International Journal of Neuropsychopharmacology. – 2008. – V. 11. – № 8. – P. 1169-1180.
23. Castrén E., Kojima M. Brain-derived neurotrophic factor in mood disorders and antidepressant treatments // Neurobiology of disease. – 2017. – V. 97. – P. 119-126.
24. Correlations and discrepancies between serum and brain tissue levels of neurotrophins after electroconvulsive treatment in rats / A. Sartorius, R. Hellweg, J. Litzke [et al.] //Pharmacopsychiatry. – 2009. – V. 42. – № 06. – P. 270-276.
25. de Assis G. G., Almondes K. M. Exercise-dependent BDNF as a modulatory factor for the executive processing of individuals in course of cognitive decline. A systematic review //Frontiers in psychology. – 2017. – V. 8. – P. 584.
26. Decreased serum brain-derived neurotrophic factor (BDNF) levels in patients with Alzheimer’s disease (AD): A systematic review and meta-analysis / T.K.S. Ng, C.S.H. Ho, W.W.S. Tam [et al.] //International journal of molecular sciences. – 2019. – V. 20. – № 2. – P. 257.
27. Duman R. S. A neurotrophic model for stress-related mood disorders / R. S. Duman, L. M. Monteggia // Biological psychiatry. – 2006. – V. 59. – № 12. – P. 1116-1127.
28. Early diagnosis of Alzheimer’s disease from elevated olfactory mucosal miR-206 level / J. Moon, S. T. Lee, I. G. Kong [et al.] // Scientific reports. – 2016. – V. 6. – № 1. – P. 1-9.
29. Effect of social isolation stress on saliva BDNF in rat / Y. Nakagawa, M. To, J. Saruta, Y. Yamamoto [et al.] //Journal of oral science. – 2019. – V. 61. – № 4. – P. 516-520.
30. Estradiol and striatal dopamine receptor antagonism influence memory system bias in the female rat / M. G. Quinlan, A. Almey, M. Caissie [et al.] // Neurobiology of learning and memory. – 2013. – V. 106. – P. 221-229.
31. Expression analysis of GRIN2B, BDNF, and IL-1β genes in the whole blood of epileptic patients / A. Zhand, A. Sayad, S. Ghafouri-Fard [et al.] // Neurological Sciences. – 2018. – V. 39. – №. 11. – P. 1945-1953.
32. Gan K. J. Dendritic and axonal mechanisms of Ca2+ elevation impair BDNF transport in Aβ oligomer–treated hippocampal neurons / K. J. Gan, M. A. Silverman // Molecular biology of the cell. – 2015. – V. 26. – №. 6. – P. 1058-1071.
33. Hashimoto K. Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine / K. Hashimoto // Biochemical Pharmacology. – 2020. – V. 177, 113935 doi: 10.1016/j.bcp.2020.113935
34. Higher brain BDNF gene expression is associated with slower cognitive decline in older adults / A. S. Buchman, L.Yu, P. A. Boyle [et al.] // Neurology. – 2016. – V. 86. – №. 8. – P. 735-741.
35. Huang Y. Peripheral BDNF/TrkB protein expression is decreased in Parkinson’s disease but not in Essential tremor / Y. Huang, C. Huang, W. Yun // Journal of Clinical Neuroscience. – 2019. – V. 63. – P. 176-181.
36. Human hippocampal neurogenesis persists throughout aging / M. Boldrini, C. A. Fulmore, A. N. Tartt [et al.] // Cell stem cell. – 2018. – V. 22. – №. 4. – P. 589-599. e5.
37. Hyperammonemia compromises glutamate metabolism and reduces BDNF in the rat hippocampus / F. Galland, E. Negri, C. Da Ré [et al.] // Neurotoxicology. – 2017. – V. 62. – P. 46-55.
38. Illness severity and biomarkers in depression: using a unidimensional rating scale to examine BDNF / M. A. Caldieraro, E. A. Vares, L. H. Souza [et al.] // Comprehensive psychiatry. – 2017. – V. 75. – P. 46-52.
39. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication / B. Chen, D. Dowlatshahi, G. M. MacQueen [et al.] // Biological psychiatry. – 2001. – V. 50. – №. 4. – P. 260-265.
40. Karege F. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets / F. Karege, M. Schwald, M. Cisse //Neuroscience letters. – 2002. – V. 328. – №. 3. – P. 261-264.
41. Libman-Sokołowska M. BDNF as a biomarker in the course and treatment of schizophrenia / M. Libman-Sokołowska, E. Drozdowicz, T. Nasierowski // Psychiatr. Pol. – 2015. – V. 49. – №. 6. – P. 1149-1158.
42. Lima S. M. A. Neurogenesis in the hippocampus of adult humans: controversy "fixed" at last / S. M. A. Lima, W. Gomes-Leal // Neural regeneration research. – 2019. – V. 14. – №. 11. – P. 1917.
43. McGregor C. E., English A. W. The role of BDNF in peripheral nerve regeneration: activity-dependent treatments and Val66Met / C. E. McGregor, A. W. English // Frontiers in cellular neuroscience. – 2018. – V. 12.
44. Meta-analyses of comparative efficacy of antidepressant medications on peripheral BDNF concentration in patients with depression / C. Zhou, J. Zhong, B. Zou [et al.] // PLoS One. – 2017. – V. 12. – №. 2.
45. Murer M.G. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease / M.G. Murer, Q. Yanb, R. Raisman-Vozari // Progress in Neurobiology. – 2001. – V. 63. – P. 71-124. DOI: 10.1016/s0301-0082(00)00014-9
46. Neurotrophin expression in lymphocytes: a powerful indicator of degeneration in Parkinson’s disease, amyotrophic lateral sclerosis and ataxia / A. Sadanand, A. Janardhanan, A.J. Vanisree [et al.] //Journal of Molecular Neuroscience. – 2018. – V. 64. – №. 2. – P. 224-232.
47. Novkovic T. BDNF contributes to the facilitation of hippocampal synaptic plasticity and learning enabled by environmental enrichment / T. Novkovic, T. Mittmann, D. Manahan-Vaughan // Hippocampus. – 2015. – V. 25. – №. 1. – P. 1-15.
48. Peripheral brain-derived neurotrophic factor levels in Alzheimer’s disease and mild cognitive impairment: a comprehensive systematic review and meta-analysis / B.Y. Kim, S.H. Lee, P.L. Graham [et al.] //Molecular neurobiology. – 2017. – V. 54. – №. 9. – P. 7297-7311
49. Plasma brain-derived neurotrophic factor daily variations in men: correlation with cortisol circadian rhythm / S. Begliuomini, E. Lenzi, F Ninni [et al.] // Journal of Endocrinology. – 2008. – V. 197. – №. 2. – P. 429-436.
50. Postmortem brain, cerebrospinal fluid, and blood neurotrophic factor levels in Alzheimer’s disease: a systematic review and meta-analysis / Y. Du, H. T. Wu, X. Y. Qin [et al.] // Journal of Molecular Neuroscience. – 2018. – V. 65. – №. 3. – P. 289-300.
51. Pradhan J. The role of altered BDNF/ TrkB signalling in amyotrophic lateral sclerosis / J. Pradhan, P. G. Noakes, M. C. Bellingham // Frontiers in cellular neuroscience. – 2019. – V. 13. – P. 368.
52. Presence of brain-derived neurotrophic factor in brain and human and rat but not mouse serum detected by a sensitive and specific immunoassay / S.F. Radka, P.A. Hoist, M. Fritsche [et al.] //Brain research. – 1996. – V. 709. – №. 1. – P. 122-130.
53. Robust changes in expression of brain-derived neurotrophic factor (BDNF) mRNA and protein across the brain do not translate to detectable changes in BDNF levels in CSF or plasma / T.A. Lanz, S.E. Bove, C.D. Pilsmaker [et al.] //Biomarkers. – 2012. – V. 17. – №. 6. – P. 524-531.
54. Selective endovascular cooling for stroke entails brain-derived neurotrophic factor and splenic IL-10 modulation / S. Corey, D.I. Abraham, Y. Kaneko [et al.] // Brain Research. – 2019. – V. 1722, Art 146380. DOI: 10.1016/j.brainres.2019.146380
55. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N= 9484) / M. L. Molendijk, P. Spinhoven, M. Polak [et al.] // Molecular psychiatry. – 2014. – V. 19. – №. 7. – P. 791-800.
56. Serum BDNF concentrations show strong seasonal variation and correlations with the amount of ambient sunlight / M.L. Molendijk, J.P. Haffmans, B.A. Bus [et al.] //PloS one. – 2012. – V. 7. – №. 11.
57. Serum Levels of Brain-Derived Neurotrophic Factor and Insulin-Like Growth Factor 1 Are Associated With Autonomic Dysfunction and Impaired Cerebral Autoregulation in Patients With Epilepsy / S.F. Chen, S.B. Jou, N.C. Chen [et al.] //Frontiers in neurology. – 2018. – V. 9. – P. 969.
58. Shetty A. K. Hippocampal neurotrophin levels in a kainate model of temporal lobe epilepsy: a lack of correlation between brain-derived neurotrophic factor content and progression of aberrant dentate mossy fiber sprouting / A. K. Shetty, V. Zaman, G. A. Shetty // Journal of neurochemistry. – 2003. – V. 87. – №. 1. – P. 147-159.
59. Stressful life events and the brain-derived neurotrophic factor gene in bipolar disorder / G. M. Hosang, R. Uher, R. Keers [et al.] // Journal of affective disorders. – 2010. – V. 125. – №. 1-3. – P. 345-349.
60. Sun H. S. Epigenetics of the depressed brain: role of histone acetylation and methylation / H. S. Sun, P. J. Kennedy, E. J. Nestler // Neuropsychopharmacology. – 2013. – V. 38. – №. 1. – P. 124-137.
61. Tanila H. The role of BDNF in Alzheimer's disease. – 2017.
62. The human BDNF gene: peripheral gene expression and protein levels as biomarkers for psychiatric disorders / A. Cattaneo, N. Cattane, V. Begni [et al.] // Translational psychiatry. – 2016. – V. 6. – №. 11. – P. e958-e958.
63. The impact of antidepressant treatment on brain-derived neurotrophic factor level: An evidence-based approach through systematic review and meta-analysis / V. Arumugam, V. S. John, N. Augustine [et al.] // Indian journal of pharmacology. – 2017. – V. 49. – №. 3. – P. 236
64. The Level of proBDNF in Blood Lymphocytes Is Correlated with that in the Brain of Rats with Photothrombotic Ischemic Stroke / H. Y. Luo, M. Rahman, L. Bobrovskaya [et al.] // Neurotoxicity research. – 2019. – V. 36. – №. 1. – P. 49-57.
65. The Role of the Microenvironmental Niche in Declining Stem-Cell Functions Associated with Biological Aging / N.A. DeCarolis, E.D. Kirby, T. Wyss-Coray [et al.] // Cold Spring Harbor Perspectives in Medicine. – 2015. – V. 5. – pii: a025874.
66. Tongiorgi E. What is the biological significance of BDNF mRNA targeting in the dendrites? / E. Tongiorgi, L. Domenici, M. Simonato // Molecular neurobiology. – 2006. – V. 33. – №. 1. – P. 17-32.
67. Transport of brain-derived neurotrophic factor across the blood–brain barrier / W. Pan, W. A. Banks, M. B. Fasold [et al.] // Neuropharmacology. – 1998. – V. 37. – №. 12. – P. 1553-1561.
68. Walsh J.J. Exercise and circulating BDNF: Mechanisms of release and implications for the design of exercise interventions / J.J. Walsh, M.E. Tschakovsky // Appl Physiol Nutr Metab. – 2018. –V. 43, N11. – Pp. 1095-1104. doi: 10.1139/apnm2018-0192.
69. West A. E., Pruunsild P., Timmusk T. Neurotrophins: transcription and translation / A. E. West, P. Pruunsild, T. Timmusk // Neurotrophic factors. – Springer, Berlin, Heidelberg, 2014. – P. 67-100.
Рецензия
Для цитирования:
Швайковская А.А., Жанаева С.Я., Евсюкова А.В., Тихонова М.А., Даниленко К.В., Афтанас Л.И. Нейротрофический фактор мозга (BDNF) и его диагностическая значимость при измерении в крови: аналитический обзор. Якутский медицинский журнал. 2020;(3):105-110. https://doi.org/10.25789/YMJ.2020.71.27
For citation:
Shvaikovskaya A.A., Zhanaeva S.Y., Evsyukova A.V., Tikhonova M.A., Danilenko K.V., Aftanas L.I. Brain neurotrophic factor (bdnf) and its diagnostic significance when measured in blood: analytical review. Yakut Medical Journal. 2020;(3):105-110. (In Russ.) https://doi.org/10.25789/YMJ.2020.71.27
Просмотров:
41
JATS XML
Послать статью по эл. почте 